Lipofit Extreme Fat Burner 2.0 recalled over fluoxetine and DNP
The company announced the recall on August 27, 2026, and the FDA published the notice on August 31, 2026. Stop using the affected product immediately. Read the FDA recall notice.
Consumers can identify the affected Lipofit Extreme Fat Burner 2.0 by checking for lot 25M12F and expiration date 09/2027, then stop using it and contact the company for return and disposal instructions. FDA laboratory analysis found undeclared fluoxetine in the daytime tablets and undeclared 2,4-dinitrophenol, or DNP, in the nighttime tablets, according to the FDA recall notice.
At a glance
- Product: Lipofit Extreme Fat Burner 2.0, packaged as daytime and nighttime tablets.
- Affected lot: 25M12F.
- Expiration date: 09/2027.
- Recall level: Consumer level, covering product sold directly to individual consumers through online sales in the United States.
- Company action: Ana Salazar Modela Tu Cuerpo Inc. stopped selling and promoting the affected product and quarantined remaining inventory under its control.
- Adverse-event reports: The company said it had not received any known reports of adverse events related to the recall as of the announcement.
The dates come from different records. The company announcement was dated August 27, 2026, while the FDA published the notice on August 31, 2026. The FDA health-fraud recall list also records the Lipofit recall under August 31, 2026.
Affected product
The recalled item is Lipofit Extreme Fat Burner 2.0, sold as a weight-loss product with AM and PM tablets.
The manufacturer said the product had been distributed in the United States directly to individual consumers through online sales. It was sold as a dietary supplement even though the FDA characterized it as an unapproved new drug for which safety and efficacy had not been established.
What the FDA found
FDA laboratory analysis found two undeclared active substances:
- Fluoxetine in the daytime tablets. Fluoxetine is an active ingredient in an FDA-approved drug used for conditions including depression, bulimia and obsessive-compulsive disorder.
- 2,4-Dinitrophenol, or DNP, in the nighttime tablets. DNP is a toxic substance commonly used as a pesticide, dye, wood preservative and herbicide.
The company announcement states that products containing fluoxetine and DNP cannot be marketed as dietary supplements. The FDA had warned consumers in June not to purchase the product after the initial detection, according to the source article, which attributed that earlier warning to FDA notifications.
What to do now
- Check the bottle. Look for lot 25M12F and expiration date 09/2027. The FDA notice identifies that exact combination as the recalled product.
- Stop using it immediately. Do not take either the daytime or nighttime tablets from the affected lot.
- Keep it away from children and other people. Do not sell, give or transfer the product to anyone else.
- Contact the company for instructions. Call Ana Salazar Modela Tu Cuerpo Inc. at 954-305-1004 or email [email protected]. Do not mail or dispose of the product until return or disposal instructions are provided.
Possible symptoms and when to seek care
The company’s FDA-posted risk statement lists nausea, vomiting, sweating, dizziness and headaches among possible effects.
People who have taken the affected product and experienced problems that may be related to it should contact their physician or healthcare provider.
Why these ingredients are not permitted in supplements
Fluoxetine is a prescription-drug active ingredient, while DNP is a toxic substance with no FDA-approved use. Their presence made the product an unapproved new drug under the company’s account of the issue.
DNP also has a documented history as a weight-loss substance. The source article says it was marketed in the 1930s until reports of deaths and blindness led to stronger federal drug regulation and an eventual FDA ban. It cites a 2011 review by United Kingdom researchers that described rapid weight loss alongside the possibility of death. The earlier review was not supplied as a linked full-text source in the research material, so its methods and sample size cannot be described from the available records.
The wider regulatory pattern is documented in the supplied research. The Hong Kong Department of Health Drug Office listed several 2026 notices involving undeclared pharmaceutical ingredients, including products containing sildenafil, tadalafil, dapoxetine, diclofenac and DMAA. The list includes a September 16, 2026 notice for biQ-FEL because of undeclared sildenafil and tadalafil, and an October 26, 2026 notice for Ultimate Forza because of undeclared sildenafil, tadalafil and dapoxetine. Those separate cases do not establish how the Lipofit product reached consumers, but they document other recalls involving ingredients absent from labels.
What remains unconfirmed
The FDA notice does not report a count of consumers who used the product, a count of bottles sold or a laboratory-measurement range for either adulterant. It does not say how the substances entered the product. The source article also does not identify adverse events associated specifically with Lipofit use.
The statement that the product was sold as an unapproved new drug comes from the FDA-posted company announcement. The source article separately identifies the earlier June FDA warning and provides historical background on DNP.
FAQ
Had adverse events been reported for the Lipofit recall?
At the time of the recall announcement, Ana Salazar Modela Tu Cuerpo Inc. said it had not received any known reports of adverse events related to the recall.
